Tenecteplase Treatment in Ischemic Stroke Registry

Study Overview
=================
Brief Summary
-----------------
The Tenecteplase Treatment in Acute Ischemic Stroke (TETRIS) Registry is multicenter ambispective observational study of patients with acute ischemic stroke who received intravenous thrombolysis with Tenecteplase

Detailed Description
-----------------
Acute ischemic stroke management has considerably evolved over the last 20 years with the development of reperfusion treatments: intravenous thrombolysis (IVT) with alteplase, which is effective for AIS within 4.5 hours from symptoms onset and up to 9 hours in some cases; and mechanical thrombectomy (MT), in AIS with large vessel occlusion (LVO) within 24 hours from symptoms onset, either after IVT (bridging therapy) or alone in case of IVT contra-indication. Alteplase is a recombinant form of tissue plasminogen activator (rtPA) that, when bound to fibrin, will activate plasminogen and lead to fibrinolysis and clot dissolution. It is administered at a dose of 0.9 mg/kg (maximum 90 mg) with an intravenous bolus (10% of the dose) followed by a one-hour infusion. Tenecteplase is a genetically modified form of alteplase with greater fibrin specificity and a longer half-life, which allows a simpler one bolus administration at a dose of 0.25 mg/kg (maximum 25 mg). In the Tenecteplase versus Alteplase before Endovascular Therapy for Ischemic Stroke (EXTEND-IA TNK) randomized clinical trial, which compared tenecteplase and alteplase in bridging therapy for AIS with LVO, tenecteplase achieved a better recanalization rate on arteriography before MT and a better functional outcome at 3 months. Following this trial, tenecteplase was added in stroke guidelines as an alternative to alteplase for IVT in bridging therapy. More recently, the Alteplase compared to Tenecteplase (ACT) trial has shown, in patients with LVO and non-LVO AIS, that tenecteplase is non-inferior to alteplase in terms of functional outcome. It is likely that in the near future tenecteplase will be added as an alternative to alteplase for AIS without LVO. However, while some real-life studies have been published on tenecteplase use for AIS with LVO, data on the general use of tenecteplase are still scarce. The Tenecteplase Treatment in Acute Ischemic Stroke (TETRIS) Registry is multicenter ambispective observational study of patients with acute ischemic stroke who received intravenous thrombolysis with Tenecteplase. The main aim of this registry is to provide routine clinical care data on the use of tenecteplase for IVT for both AIS with and without LVO, in order to further characterize the safety and efficacy of tenecteplase for AIS. Additionally, we aim to use this registry which combines clinical and radiological data to explore other aspects related to AIS management in this cohort.

Official Title
-----------------
Tenecteplase Treatment in Ischemic Stroke Registry

Conditions
-----------------
Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and older Confirmed acute arterial ischemic stroke on brain imaging (CT or MRI) within 270 minutes of symptoms onset or with perfusion CT or MRI criteria for an extended treatment window or wake-up strokes. Intravenous thrombolysis with tenecteplase Exclusion Criteria: Contra-indication to intravenous thrombolysis Intravenous thrombolysis with alteplase Venous ischemic stroke

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tenecteplase<br>All consecutive patients with an arterial acute ischemic stroke treated with intravenous thrombolysis with tenecteplase. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional outcome | Modified Rankin score (mRS), score ranging from 0 (no symptom) to 6 (death). | Day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy on functional independence (mRS ≤ 2) | Rate of functional independence defined as a modified Rankin score 0-2 | Day 90 | 
| Mortality rate | Rate of all-cause mortality | Day 90 | 
| Early neurological outcome | National Institutes of Health Stroke Scale (NIHSS) score after 24 hours, ranging from 0 (no symptom) to 42 (death) | Day 1 | 
| Incidence of haemorrhagic transformation | Incidence of intracerebral haemorrhage on MRI or CT after 24 hours (±12 hours) according to the ECASS II classification. | Day 1 | 
| Incidence of symptomatic intracerebral haemorrhage (sICH) | Incidence of sICH according to the SITS-MOST definition. | Day 1 | 
| Pre-thrombectomy recanalization rate | Rate of complete or near complete recanalization, defined as an extended Thrombolysis in Cerebral Infarction (mTICI) 2b50/2b66/2c/3 before thrombectomy | Day 1 | 
| Final recanalization rate | Rate of complete or near complete recanalization after | Day 1 | 
| Thrombolysis complication rate | Rate of complications linked to intravenous thrombolysis with tenecteplase | Day 1 | 
| Thrombectomy complication rate | Rate of patients with secondary decompressive craniectomy | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke, Ischemic stroke, Thrombolytic therapy, Tenecteplase, Thrombectomy, Cerebrovascular Disorders, Brain diseases, Central Nervous Diseases, Nervous system Diseases, Vascular Diseases, Cardiovascular Diseases